Clinical Trial: SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic Syndromes

Brief Summary: The purpose of this study is to determine the safety and effectiveness of oral SCIO-469 in patients with myelodysplastic syndromes. SCIO-469 belongs to a new class of treatments that inhibit expression and activity of cytokines that play a role in the progression of MDS.